We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prediction of Acute Rejection in Renal Transplant

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00205257
First Posted: September 20, 2005
Last Update Posted: October 5, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Wisconsin, Madison
September 13, 2005
September 20, 2005
October 5, 2015
September 2001
February 2007   (Final data collection date for primary outcome measure)
kidney biopsy pathology [ Time Frame: 1 year ]
kidney biopsy pathology
Complete list of historical versions of study NCT00205257 on ClinicalTrials.gov Archive Site
urinary chemokines [ Time Frame: 1 year ]
Not Provided
Not Provided
Not Provided
 
Prediction of Acute Rejection in Renal Transplant
Prediction of Acute Graft Rejection by Examining Urine Chemokines in Patients With Kidney Transplant
Acute rejection is still a major risk factor affecting the prognosis of kidney transplant patients. Alloreactive cells of the recipient infiltrate the kidney graft and cause inflammatory reaction which damages the graft structure and function. Conventional diagnosis of acute rejection is based on clinical symptoms and kidney biopsy examination. The clinical symptoms are a result of the kidney damage, which occurs days after the initiation of the rejection reaction. Kidney biopsy is an invasive and expensive procedure. It has been wished to have new parameters that can replace/supplement the conventional procedures. Chemokines are small molecules that attract inflammatory cells. Changes of chemokine levels in the urine may correlate with the immune status in the kidney. A systematic study to evaluate the chemokine levels in urine and correlation with the kidney biopsy pathology will answer the question whether monitoring of urinary chemokines would be useful in predicting graft rejection/damage.
Not Provided
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Kidney Transplant
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
February 2007
February 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • One hundred subjects undergoing kidney biopsy for suspected rejection
  • Forty subjects that have stable graft function with normal level of blood creatinine (No biopsy is needed at the time of sample collection).

Exclusion Criteria:

  • Subjects under the age of 18
  • Gender of potential subjects male or female
  • Age Limits greater than 18 years of age
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00205257
2001-252
Not Provided
Not Provided
Not Provided
University of Wisconsin, Madison
University of Wisconsin, Madison
Not Provided
Principal Investigator: Thomas Chin University of Wisconsin Medical School
University of Wisconsin, Madison
December 2013